ArticleFrontiers in molecular biosciences2026
Peripheral blood circMAN1A2 as a novel diagnostic biomarker for gout: integrated transcriptomic analysis and clinical validation.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout is one of the most common inflammatory arthritides. Although identification of monosodium urate crystals in synovial fluid is the diagnostic gold standard, the invasive procedure limits routine use. Non-invasive biomarkers are needed to facilitate timely diagnosis of acute gout flares and to differentiate gout from asymptomatic hyperuricaemia. Methods: Differential expression analysis was performed using the GEO circRNA microarray dataset GSE178825 (peripheral blood mononuclear cells, PBMCs; gout vs. healthy controls). Differentially expressed circRNAs were mapped to their host genes, followed by host-gene-based functional enrichment and protein-protein interaction (PPI) network analyses for candidate prioritization, circMAN1A2, derived from the MAN1A2 locus, was selected for clinical validation. PBMCs were isolated from whole blood samples obtained from 30 patients with acute gout flare, 30 individuals with HUA, and 30 healthy controls. Circularity was confirmed by RNase R resistance, and circMAN1A2 expression was quantified by RT-qPCR. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Results: Peripheral blood circMAN1A2 levels were significantly lower in patients with gout than in healthy controls, and showed a decreasing trend compared with individuals with HUA. circMAN1A2 showed preliminary diagnostic potential for gout (AUC = 0.86; 95% CI 0.66-1.00), with 90.0% sensitivity and 90.1% specificity. Conclusion: Peripheral blood circMAN1A2 is a promising candidate biomarker for gout diagnosis. Integrating public transcriptomic mining with targeted clinical validation may accelerate biomarker discovery for gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.